Meet with our product experts in one-on-one virtual sessions
Set Up a Meeting
恩扎卢胺
抗癌/抗肿瘤
Ruxolitinib Phosphate
抗癌/抗肿瘤
卡巴他赛
抗癌/抗肿瘤
卡非佐米
抗癌/抗肿瘤
吡托布鲁替尼
抗癌/抗肿瘤
呋喹替尼
抗癌/抗肿瘤
哌唑帕尼
抗癌/抗肿瘤
哌柏西利（晶型A）
抗癌/抗肿瘤
唑来磷酸
抗癌/抗肿瘤
Oncology/Anticancer API Products Manufacturer and Supplier
Dr. Reddy's is a global leader in developing APIs in the Oncology/Anti-cancer therapy area, with deep technical and scientific knowledge established over decades. With a strong presence across six continents and 39 countries, we are a partner of choice for supplying APIs to leading oncology formulators globally.
As one of the largest generic pharmaceutical manufacturers in the world, we have established a niche in generic oncology APIs and partner of choice for supplying APIs to leading oncology formulators globally.
Our various classes of API under anti-cancer portfolio are as follows:
Kinase Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
BCL-2 Inhibitor
*Countries referred in the above graphic denotes DMF filing geographies
Androgen Receptor (AR) Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Folate Analog Metabolic Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Nucleoside Metabolic Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Microtubule Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Proteasome Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Thalidomide Analogue
*Countries referred in the above graphic denotes DMF filing geographies
CYP17 Inhibitor
*Countries referred in the above graphic denotes DMF filing geographies
Bifunctional Mechlorethamine
*Countries referred in the above graphic denotes DMF filing geographies
Nucleoside Metabolic Inhibitor
*Countries referred in the above graphic denotes DMF filing geographies
Alkylating Agent
*Countries referred in the above graphic denotes DMF filing geographies
Poly (ADP-ribose) Polymerase
*Countries referred in the above graphic denotes DMF filing geographies
CXCR4 Chemokine Receptor
*Countries referred in the above graphic denotes DMF filing geographies
GnRH Receptor Antagonist
*Countries referred in the above graphic denotes DMF filing geographies
Chemical Permeation Enhancer
*Countries referred in the above graphic denotes DMF filing geographies
Dr. Reddys Portfolio of Anti-cancer APIs
We manufacture our Anti-cancer APIs at cGMP API manufacturing facilities which are successfully inspected by international regulatory authorities such as the USFDA, EMEA, ANVISA, PMDA, and Health Canada.
Our team of process experts draws on their integrated understanding of IP, process development (API and formulation), and API manufacturing to ensure that by design, the process is lean, free from potential genotoxic impurities, and scalable to manufacture for early market entries. This is of particular importance to select the optimal synthesis route in the context of the IP situation. Other aspects are the solid-state forms and particle characteristics that are critical in formulation development.
We have incorporated sensitive and rigorous analytical methods to control the impurities at a specified level and extensively studied the flow properties, crystal size/shape, and morphology in accordance with future requirements. In addition, our APIs have been designed to address customized PSD requirements through size reduction and crystallization techniques, resulting in a high probability of successful formulation development.
USPs of our Anti-cancer APIs
- QbD approach for an efficient process & high-quality output
- Availability of APIs in various forms.
- cGMP API manufacturing facility - Successfully inspected by international regulatory authorities.
- GTIs & impurities are controlled below the TTC limit & ICH limits, respectively.
- Formulation dossier filed across all major markets.
- Regulatory filing available across the globe.
- Completely backward integrated on the Key starting materials to ensure uninterrupted supplies.
- Adequate capacity to meet the global demands.
- KSM suppliers with timely deliveries and adherence to stringent specifications.
- Process safety management guidelines are implemented to enable a sustainable product supply.
- IP-Compliant API that meets regulatory requirements.
免责声明
本網站上的任何信息，包括對任何產品或服務的任何提及，均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是，在某些情況下，雷迪博士可自行決定並根據當地法律要求，在存在此類監管豁免的任何地方，提供此類產品的研究數量，以根據《印度專利法》第 107A 條（Bolar 豁免）進行監管提交。購買者應對其各自市場的產品或服務（包括專利情況）進行獨立評估，並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證，包括但不限於適銷性、適用於特定用途和非侵權的保證。